- 2026-12-05
-
Trastuzumab deruxtecan plus bevacizumab as first-line maintenance therapy for human epidermal growth factor receptor 2-expressing ovarian cancer: Safety run-in results from DESTINY-Ovarian01
11:19-11:27
Hall B
Best Oral
Speaker

Kasumi Yamamoto
Trastuzumab deruxtecan plus bevacizumab as first-line maintenance therapy for human epidermal growth factor receptor 2-expressing ovarian cancer: Safety run-in results from DESTINY-Ovarian01
11:19-11:27
Hall B
Best Oral
Speaker